Drug intelligence / Profile preview

AT-301

Development stage: Phase 1
Lead developer: Atossa Therapeutics
Modality: Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
Administration: Intranasal

Overview

Atossa Therapeutics' AT-301 is a nasal spray drug candidate currently in a Phase 1 safety study. It is being developed for at-home use in patients recently diagnosed with COVID-19, with the goal of reducing symptoms and slowing the progression of the infection. The clinical trial is a randomized, double-blind, placebo-controlled, ascending dose, multi-cohort study, structured in two parts: a single ascending dose (SAD) and a multiple ascending dose (MAD).

Other names: AT-301BAT301BAT 301B

Beyond the preview

Go deeper on AT-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-301.

Explore the full profile